Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00498-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Maria F Mojica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Burkholderia gladioli, Burkholderia cepacia complex, Cystic Fibrosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, BLRD VA.
Abstract (Originalsprache)
The novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Burkholderia gladioli strains. The addition of taniborbactam to cefepime shifted cefepime minimum inhibitory concentrations toward the provisionally susceptible range in 59% of the isolates tested. Therefore, cefepime-taniborbactam possessed similar activity as first-line agents, ceftazidime and trimethoprim-sulfamethoxazole, supporting further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio, USA.
- Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA.
- CASE-VA Center for Antimicrobial Resistance and Epidemiology , Cleveland, Ohio, USA.
- University of Michigan , Ann Arbor, Michigan, USA.
- Venatorx Pharmaceuticals, Inc. , Malvern, Pennsylvania, USA.
- Department of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.
ORCID-Profile: Maria F Mojica, Elise T Zeiser, John J LiPuma, David A Six, Krisztina M Papp-Wallace
Förderung
- Wellcome Trust
- NIAID NIH HHS
- BLRD VA
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- U.S. Department of Health and Human Services
- U.S. Department of Veterans Affairs
- Cystic Fibrosis Foundation
Zitieren
APA
Mojica, M. F., Zeiser, E. T., Becka, S. A., LiPuma, J. J., Six, D. A., Moeck, G., & Papp-Wallace, K. M. (2023). Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00498-23
Vancouver
Mojica MF, Zeiser ET, Becka SA, LiPuma JJ, Six DA, Moeck G, et al. Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00498-23
BibTeX
@article{Mojica2023,
author = {Mojica, Maria F and Zeiser, Elise T and Becka, Scott A and LiPuma, John J and Six, David A and Moeck, Greg and Papp-Wallace, Krisztina M},
title = {Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00498-23}
}
EUVIMED